Collateral sensitivity as a strategy against cancer multidrug resistance

Kristen M. Pluchino, Matthew D. Hall, Andrew S. Goldsborough, Richard Callaghan, Michael M. Gottesman*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

269 Citations (Scopus)

Abstract

While chemotherapy remains the most effective treatment for disseminated tumors, acquired or intrinsic drug resistance accounts for approximately 90% of treatment failure. Multidrug resistance (MDR), the simultaneous resistance to drugs that differ both structurally and mechanistically, often results from drug efflux pumps in the cell membrane that reduce intracellular drug levels to less than therapeutic concentrations. Expression of the MDR transporter P-glycoprotein (P-gp, MDR1, ABCB1) has been shown to correlate with overall poor chemotherapy response and prognosis. This review will focus on collateral sensitivity (CS), the ability of compounds to kill MDR cells selectively over the parental cells from which they were derived. Insights into CS may offer an alternative strategy for the clinical resolution of MDR, as highly selective and potent CS agents may lead to drugs that are effective at MDR cell killing and tumor resensitization. Four main mechanistic hypotheses for CS will be reviewed, followed by a discussion on quantitative and experimental evaluation of CS.

Original languageEnglish
Pages (from-to)98-105
Number of pages8
JournalDrug Resistance Updates
Volume15
Issue number1-2
DOIs
Publication statusPublished - 2012
Externally publishedYes

Fingerprint

Dive into the research topics of 'Collateral sensitivity as a strategy against cancer multidrug resistance'. Together they form a unique fingerprint.

Cite this